Skip to main content
Premium Trial:

Request an Annual Quote

David Smoller and Melvin Booth

Premium

Sigma-Aldrich has named David Smoller vice president of research and development, the company said on June 10.

According to a company statement, Smoller will be expected to “help expand Sigma-Aldrich’s leadership position through the development of new and innovative products for life science and high technology research.”

Smoller founded Genome Systems in 1992, and remained president of the company until 1996, when it was acquired by Incyte. Smoller then joined Incyte as vice president, and eventually became senior vice president, his most recent position. As such, he managed that company’s genomics business, which boasted over $150 million in annual sales, Sigma-Aldrich said.

Smoller earned his PhD in molecular biology from Emory University, and completed postdocs at Washington University and Monsanto.


Millipore announced last week that it has elected Melvin Booth to its board of directors.

Most recently, Booth served as president and chief operating officer at MedImmune, a position from which he retired in January. He remains on MedImmune’s board, and also serves on the boards of Focus Technologies, Nova Screen BioSciences, and Prestwick Pharmaceuticals.

Prior to MedImmune, Booth was president and chief operating officer of Human Genome Sciences. He has also held various senior management positions at Syntex.

Booth has an honorary doctor of science degree from Northwest Missouri State University, and is a certified public accountant.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.